 |
|
|
| |
Efficacy by Race or Geographic Region in HCV Genotype 1-Infected Patients Treated With ABT-450/Ritonavir/Ombitasvir
and Dasabuvir With or Without Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
John Vierling1, Massimo Puoti 2, David Bernstein3, Naoky Tsai4, Ola Weiland5, Manuel Romero-Gómez6, Florin Alexandru Caruntu7, Jean-Francois DuFour8, Filipe Calinas9, Lois Larsen10, Fernando Tatsch10,
Pietro Andreone11
1Baylor College of Medicine and Advanced Liver Therapies, Houston, Texas, United States; 2AO Ospedale Niguarda Ca Granda, Milan, Italy; 3North Shore University Hospital, Manhasset, New York, United States; 4Queen's Medical Center, University of Hawaii, Honolulu, Hawaii, United States;
5Karolinska University Hospital Huddinge, Karolinska Insti tutet, Stockholm, Sweden; 6Hospital Universitario Nuestra Señora de Valme, Seville, Spain; 7Nati onal Insti tute for Infecti ous Diseases "Matei Bals," Bucharest, Romania; 8University Clinic for Visceral Surgery and Medicine, Bern, Switzerland;
9Centro Hospitalar Lisboa Central, EPE - Hosp. St. Antonio dos Capuchos, Lisbon, Portugal; 10AbbVie Inc., North Chicago, Illinois, United States; 11Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
|
| |
|
|
|
|
|
